Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06387511
Other study ID # NutriVax-Measles
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 7, 2024
Est. completion date June 30, 2025

Study information

Verified date June 2024
Source Alliance for International Medical Action
Contact Cécile Cazes, PhD
Phone +33 7 80 58 97 42
Email cecile.cazes@coral.alima.ngo
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Provision of SQ-LNS also holds promise in incentivizing vaccination as well as other health services. The investigators will estimate 1) the effectiveness of a SQ-LNS mass supplementation program added to routine immunization program compared to routine immunization program alone in terms of measles vaccine coverage, after 12 months of program implementation, 1) in children aged 12-23 months in the end line cross-sectional household survey, 2) in children aged 6-12 months at inclusion, in a longitudinal 12 months follow-up survey. Secondary objectives are to assess the barriers and facilitators from the perspectives of parents/legal guardian of children, health care providers and community health workers and to assess the cost-efficiency of the This study will be implemented in 20 wards covering the Karasuwa and Nguru Local Government Areas (LGAs) in Yobe state, Northeast Nigeria. This is a pragmatic parallel cluster randomized trial (PCT) with baseline measure with different populations and data collection modes: 1) baseline and end line cross-sectional household surveys of children aged 12-23 months, 2) a longitudinal follow-up survey (LS) of children aged 6-12 months at inclusion, 3) a qualitative feasibility and acceptability survey of parents of children aged 6-23 months, of health providers, of community health workers and community representatives and 4) a cost survey of parents/legal guardian of children from the longitudinal follow-up cohort, and 5) a health facility cost survey of a randomized subsample of health facilities. Clusters will be randomly allocated at a ratio of 1:1 either to the standard arm or to the NutriVax arm: - The standard Expanded Program on Immunization (EPI) in children aged 6-23 months delivered according to the Ministry of Health's routine plans in the community and at health centres and health posts, named the standard EPI arm; - The NutriVax program combining the EPI in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres (i.e. PHCCs) and health posts associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres (i.e. PHCCs) for children 6-23 months of age, named the NutriVax arm.


Description:

Background/ Rational Every year, hundreds of thousands of children are treated for severe wasting while experiencing repeated and prolonged outbreaks of vaccine-preventable illnesses, most notably measles. At least 20 million children annually still do not receive immunizations. Northeast Nigeria is at the epicentre of this dynamic, recording some of the worst malnutrition indicators and lowest vaccination coverage rates in the world. Small-quantity lipid-based nutrient supplements (SQ-LNS) are a class of ready-to-use food supplements which are highly nutrient-dense and fortified designed for preventing malnutrition and improving child survival, growth, and development. A recent meta-analysis on SQ-LNS reveals that feeding a child just one sachet of SQ-LNS a day for a year can reduce their risk of mortality by 27%, and reduce cases of severe wasting by 31% and severe stunting by 17%. The overall strength of evidence on SQ-LNS benefits led the authors of a 2021 Lancet review to call scaling-up SQ-LNS a priority action. Provision of SQ-LNS also holds promise in incentivizing vaccination as well as other health services. Primary objective To estimate the effectiveness of a SQ-LNS mass supplementation program added to routine immunization program compared to routine immunization program alone in terms of measles vaccine coverage, after 12 months of program implementation, in children aged 12-23 months in the end line cross-sectional household survey. Main secondary objective To estimate the effectiveness of a SQ-LNS mass supplementation program added to routine immunization program compared to routine immunization program alone in terms of measles vaccine coverage, after 12 months of program implementation, in children aged 6-12 months at inclusion in the longitudinal 12 months follow-up survey. Secondary objectives - To estimate the effectiveness of a SQ-LNS mass supplementation program added to routine immunization program compared to routine immunization program alone in children aged 6-23 months, after 12 months of program implementation, in terms of 1) all other infant vaccines' uptake, 2) timeliness of age-eligible vaccinations; 3) anthropometric status, 4) uptake of paediatric curative and preventive health consultations and activities. - To assess the barriers and facilitators to SQ-LNS mass supplementation implemented as part of a routine immunization program in health facilities, from the perspectives of parents/legal guardian of children aged 6-23 months, health care providers and community health workers. - To assess the cost-efficiency of a SQ-LNS mass supplementation program compared to routine immunization program in terms of cost per child supplemented and vaccinated. Study sites : 20 wards covering the Karasuwa and Nguru Local Government Areas (LGAs) in Yobe state, Northeast Nigeria Study design A pragmatic parallel cluster randomized trial (PCT) with baseline measure with different populations and data collection modes: 1) baseline and end line cross-sectional household surveys of children aged 12-23 months, 2) a longitudinal follow-up survey (LS) of children aged 6-12 months at inclusion, 3) a qualitative feasibility and acceptability survey of parents of children aged 6-23 months, of health providers, of community health workers and community representatives and 4) a cost survey of parents/legal guardian of children from the longitudinal follow-up cohort, and 5) a health facility cost survey of a randomized subsample of health facilities. Interventions compared 1. The standard Expanded Program on Immunization (EPI) in children aged 6-23 months delivered according to the Ministry of Health's routine plans in the community and at health centres and health posts, named the standard EPI arm. 2. The NutriVax program combining the EPI in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres (i.e. PHCCs) and health posts associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres (i.e. PHCCs) for children 6-23 months of age, named the NutriVax arm. The unit of randomization (cluster) will be the ward and its catchment area. Clusters will be randomly allocated at a ratio of 1:1 either to the standard EPI arm or to the NutriVax arm. Statistical analyses Differences in measles vaccine coverage (dose 1) between control and intervention arms at end line will be assessed using multilevel regression models. The study will be conducted in compliance with the protocol, the Declaration of Helsinki, the GCP guidelines and the Nigerian National Code for Health Research Ethics Timeline : 2 years (December 2023-December 2025)


Recruitment information / eligibility

Status Recruiting
Enrollment 3720
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 23 Months
Eligibility - Baseline and endline cross-sectional household surveys Inclusion criteria - Aged 12-23 months; - With oral informed consent of parent or legal guardian; - Residing in the catchment settlements of wards included in the study. Exclusion criteria - Included in the longitudinal follow-up. - Longitudinal follow-up survey Inclusion criteria - Aged 6-12 months; - With written informed consent of parent or legal guardian; - Residing in the catchment settlements of wards included in the study. Exclusion criteria - Acute malnutrition criteria as per the WHO definition (i.e. MUAC< 125 or WHZ < -2 or nutritional edema); - - Known medical complication that requires referral for hospitalization; - Known allergies to SQ-LNS or SQ-LNS contraindication; - Any other condition interfering with protocol adherence or the ability to give informed consent, in the judgment of the Field Investigator Sampling for HHS and LS will be carried out in three stages in each LGA using probability proportional to size (PPS). - Qualitative feasibility and acceptability survey Inclusion - Parent or legal guardian of a child aged 6-23 months and residing in the catchment settlements of wards included in the study, or Health worker of the ministry of health involved in the study,or Community representative or Community health workers; - With written informed consent. Exclusion criteria - None

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax
The intervention tested combines the delivery of the Expanded Program on Immunization (EPI) in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres for children 6-23 months of age.

Locations

Country Name City State
Nigeria All Primary Health Care Centers of Nguru and Karasuwa LGAs Damaturu Yobe

Sponsors (6)

Lead Sponsor Collaborator
Alliance for International Medical Action Eleanor Crook Foundation, Gavi, The Vaccine Alliance, Institut National de la Santé Et de la Recherche Médicale, France, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Yobe State Ministry of Health, Nigeria

Country where clinical trial is conducted

Nigeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measles vaccine coverage in children aged 12-23 months The proportion of children aged 12-23 months in the endline survey who have received at least one dose of measles vaccine, as reported on their vaccination card. Measured after one year after of intervention implementation.
Primary Measles vaccine coverage in children 6-12 months at inclusion The proportion of children aged 6-12 months at inclusion in the longitudinal follow-up survey, who have received at least one additional dose of measles vaccine, as reported on their vaccination card, administered between inclusion and the end of follow-up. Measured after one year after of intervention implementation.
Secondary Measles vaccine coverage: at least one dose The proportion of children with at least one measles vaccine as reported on a vaccination card or by recall. Measured after one year after of intervention implementation.
Secondary Measles vaccine coverage : two doses The proportion of children with a measles 2 vaccine as reported on a vaccination card or by recall Measured after one year after of intervention implementation.
Secondary Timeliness of measles 1 vaccination Proportion of children with Measles 1 vaccine received within 30 days of turning 9 months by card Measured after one year after of intervention implementation.
Secondary Other infant vaccines coverage Proportion of children with Pentavalent 1 and 3, yellow fever, meningitis vaccine as reported on a vaccination card or by recall Measured after one year after of intervention implementation.
Secondary Zero-dose Proportion of children with No measles + pentavalent + yellow fever + meningitis vaccines reported on a vaccination card or by recall. Measured after one year after of intervention implementation.
Secondary Fully immunization Proportion of children who had received all childhood vaccinations recommended by the Nigeria MOH. Measured after one year after of intervention implementation.
Secondary Acceptability Barriers and facilitators to access health care centres and receive SQ-LNS mass supplementation implemented as a routine preventive program nested in health facilities activities Measured after 2 months and one year after of intervention implementation.
Secondary Cost-efficiency • Cost per child vaccinated and supplemented compared to cost per child vaccinated only, using a facility and caregiver perspectiveto identify all provider and caregiver costs associated with treatment. Measured after one year after of intervention implementation.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Recruiting NCT05867433 - Strong Teens for Healthy Schools Change Club: A Civic Engagement Approach to Improving Physical Activity and Healthy Eating Environments N/A
Completed NCT02376530 - Price Changes and Nutrient Profiling Among Adult Grocery Shoppers N/A
Completed NCT01040975 - Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight N/A
Completed NCT00957814 - Nutritional Orientations and Adherence, Nutritional Status, Clinical and Life Quality Parameters of Heart Failure (HF) Patients N/A
Completed NCT00808756 - Study on Fermentable Carbohydrates in Healthy Infants N/A
Completed NCT03290118 - The Efficacy of Front-of-package Labelling Schemes: an Experimental Study N/A
Completed NCT03575884 - Fit 5 Kids Screen Time Reduction Curriculum for Latino Preschoolers N/A
Completed NCT03963778 - Organisational Culture and Nutritional Care
Completed NCT05633251 - Using Reinforcement Schedules to Increase Fruit&Vegetable Intake, Reduce Waste, and Increase School Lunch Participation N/A
Recruiting NCT05977959 - Optimizing the Impact of the Healthy School Recognized Campus Program on Youth's CVD Risk Factors N/A
Recruiting NCT05138276 - Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates Early Phase 1
Completed NCT03906851 - Active and Healthy Kids in Telemark - a School Based Health Promoting Intervention N/A
Not yet recruiting NCT02950779 - Assessment of Handgrip Strength in Adults With Inflammatory Bowel Disease N/A
Completed NCT02486588 - Increasing Engagement With a Healthy Food Benefit N/A
Withdrawn NCT01184027 - Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment N/A
Completed NCT01178398 - Understanding Fish Consumption Habits During Pregnancy N/A
Completed NCT01249508 - Nutrition Labeling Program to Promote Healthy Dietary Patterns N/A
Terminated NCT00577499 - Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis N/A
Completed NCT00109551 - Community Trial of Zinc Supplementation on Preschool Child Mortality and Morbidity in Southern Nepal Phase 3